asthma. Severe persistent asthma with (acute) exacerbation
Conditions
Interventions
Intervention 1: Intervention group: patients with acute asthma, nebulized budezonide(pulmicort) will be administered with the dose of 0.5 mg every half an hour up to three dose in additional standard
Sponsors
Astra Zeneca
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age > 18 with signed informed consent letter Patients with acute asthma(moderate to severe)
Exclusion criteria
Exclusion criteria: Unwillingness of patients to participate in the study Patients with COPD Pneumonia Pneumothorax CHF Acute and severe respiratory failure with cyanosis and confusion Loss of consciousness Pregnant patients Smokers Intubated patients and patients with unstable vital signs New case of asthma Hemodynamic instability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of vital sign and clinical symptoms in patients with asthma attack. Timepoint: At the begining of the study(before intervention), 30, 60, 180 minutes after treatment. Method of measurement: physical exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relief of acute asthma attack(sign and symptom)from patient and dr "view. Timepoint: During the treatment in emergency center. Method of measurement: by completing questionnaire form, follow up, ask question about the number of readmission rate and length of hospitalization. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmaryam habibi samadi
Tehran University of Medical Sciences
Outcome results
None listed